Elinor Langfelder-Schwind received her B.S. in Biology and Society from Cornell University in 1990, M.S. in Human Genetics from Sarah Lawrence College in 1995, and certification from the American Board of Medical Genetics/American Board of Genetic Counseling in 1996. Elinor began her career in CF genetics in 1990 as a Program Analyst in the Ethical, Legal, and Social Implications Program of the National Center for Human Genome Research (now NHGRI) where she helped to coordinate the pilot studies on implementing CF carrier screening in the general population. She has worked with adult and pediatric patients as a genetic counselor in accredited CF Centers since 1995, initially at St. Vincent's Hospital in New York City, and she currently holds the position at Mount Sinai Beth Israel.
Elinor is an active participant in the New York State CF newborn screening consortium, National Society of Genetic Counselors' CFTR Spectrum Disorders Special Interest Group, and first author of the NSGC Practice Recommendations on CF screening. She is a site administrative and regulatory research coordinator for gene modulation and other research studies, as well as coordinator for genetic modifier studies and a state-wide QI initiative to improve the process of newborn screening follow up in New York State. Elinor educates genetic counseling students from Sarah Lawrence College about CF as a clinical training site coordinator, thesis advisor, and lecturer. Elinor has been an advocate of educating patients, professionals and the public about CF newborn screening, having developed CF NBS educational materials for New York State, served on the workgroup for the CF Foundation's Newborn Screening website content development, and is an adjunct member of the CLSI CF Newborn Screening working group. Elinor chaired the Genetic Services Committee and served on the Board of Directors of the NSGC from 2005-2007 and is recognized nationally for her contributions to the field of CF genetic counseling.